Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Assembly BiosciencesASMB +0.25%34 3-Year FCF Growth Rate is 44.10% as of Jun. 2026, which is 31% above its 10-year median of 33.75. GuruFocus rates ASMB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,110 Biotechnology companies, Assembly Biosciences ranks better than 78.38% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 44.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Assembly Biosciences was 52.70% per year. The lowest was -33.90% per year. And the median was 33.75% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Assembly Biosciences 3-Year FCF Growth Rate Related Terms
ASMB vs ZURA, ARVN, ARTV: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Assembly Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 44.10% mean?
Assembly Biosciences (ASMB) has a 3-Year FCF Growth Rate of 44.10% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Assembly Biosciences and its competitors. This is 31% above median its historical median of 33.75. According to the industry distribution chart, Assembly Biosciences ranks #240 out of 1110 companies in the Biotechnology industry, placing it in the top 21.6%.
Is Assembly Biosciences' 3-Year FCF Growth Rate too high?
Assembly Biosciences' current 3-Year FCF Growth Rate of 44.10% is 31% above median its 10-year median of 33.75. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. Assembly Biosciences' value of 44.10% is 128.5% above this industry median. Based on the distribution chart, Assembly Biosciences ranks #240 out of 1110 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' 3-Year FCF Growth Rate compare to ZURA and ARVN?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #240 out of 1110 companies for 3-Year FCF Growth Rate. This places Assembly Biosciences in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 19.30. Assembly Biosciences' value of 44.10% is 128.5% above this benchmark. While the company's 10-year median is 33.75 vs. the industry median of 19.30, Assembly Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,110 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current 3-Year FCF Growth Rate of 44.10% is 128.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Assembly Biosciences and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current 3-Year FCF Growth Rate is 44.10%, which is 31% above median its own 10-year median of 33.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current 3-Year FCF Growth Rate of 44.10%. The current 3-Year FCF Growth Rate is 44.10%, which is 31% above median its 10-year median of 33.75 and 128.5% above the Biotechnology industry median of 19.30. Assembly Biosciences' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current 3-Year FCF Growth Rate is 44.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
34GF Score
Get the complete analysis for ASMB
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
